{"entity":{"id":"atx-898","kind":"drug","name":"ATX-898","aka":[],"tldr":"ATX-898 is an experimental small molecule from Antares Therapeutics, in phase 1 trials for advanced solid tumours, platinum-resistant ovarian cancer and other gynaecological cancers and other cancers.","summary":"ATX-898 is a small molecule (registry lists it as a drug; the company does not publish the modality for this code) from Antares Therapeutics. Not disclosed. The registry describes a first-in-human study of ATX-898 alone and with other anticancer drugs; no source reached names its target. Its furthest stage is phase 1, for advanced solid tumours, platinum-resistant ovarian cancer, other gynaecological cancers and HR-positive HER2-negative breast cancer (with fulvestrant plus abemaciclib or ribociclib). ClinicalTrials.gov registers it in one study linked below. Phase 1/2 study NCT07767474 recruiting; actual start 31 August 2026 (ClinicalTrials.gov). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Antares Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07767474"},{"label":"Antares Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07767474"},{"label":"Antares Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07767474"},{"label":"Antares Therapeutics: antaresrx.com","url":"https://antaresrx.com/"},{"label":"ClinicalTrials.gov: trials of ATX-898","url":"https://clinicaltrials.gov/search?intr=ATX-898"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["antares-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07767474"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ATX-898","modality":"Small molecule (registry lists it as a drug; the company does not publish the modality for this code)","mechanism":"Not disclosed. The registry describes a first-in-human study of ATX-898 alone and with other anticancer drugs; no source reached names its target.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/atx-898/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"antares-therapeutics","kind":"company","name":"Antares Therapeutics","route":"/companies/antares-therapeutics/"}],"trial":[{"id":"nct07767474","kind":"trial","name":"A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors","route":"/trials/nct07767474/"}]}}